| Patent Number |
Title Of Patent |
Date Issued |
| 7262177 |
Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers |
August 28, 2007 |
| A conjugate of formula A-L-P, in which: A represents a glycosylated/galactosylated peptide that binds to a cell-surface receptor, L represents a bifunctional linker, which does not comprise a naturally occurring amino acid and is covalently bonded to A and P in a regiospecific mann |
| 6960449 |
Class characterization of circulating cancer cells isolated from body fluids and methods of use |
November 1, 2005 |
| The present invention relates to the identification and characterization of classes and subclasses of circulating cancer cells, including microtumors from body fluid samples using molecular, cytological, and morphological analyses, and methods for staging patients and measuring the effic |
| 6906182 |
Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers |
June 14, 2005 |
| A conjugate of formula A-L-P, in which: A represents a glycosylated/galactosylated peptide that binds to a cell-surface receptor, L represents a bifunctional linker, which does not comprise a naturally occurring amino acid and is covalently bonded to A and P in a regiospecific mann |
| 6080726 |
Anti-viral and immuno stimulator polynucleotide duplex and use thereof |
June 27, 2000 |
| A method of treating HSV-2 infection which comprises administering to a host subject to said infection an effective amount of a polynucleotide of the formula polyrI.polyr(C.sub.12 U) where n is an integer from 4 to 29. The polynucleotide is advantageously administered intranasally. |
| 6005094 |
Oligonucleotide analogues having improved stability at acid pH |
December 21, 1999 |
| Acid resistant Oligomers suitable for oral administration, orally acceptable formulations of such Oligomers and preparation of pharmaceutical formations of such Oligomers are provided. |
| 5994517 |
Ligands to enhance cellular uptake of biomolecules |
November 30, 1999 |
| Oligodeoxynucleoside methylphosphonate neoglycopeptide conjugates and related compounds for tissue specific delivery of biologically stable, nonionic oligodeoxynucleoside analogs into cells. |
| 5962237 |
Method of enriching rare cells |
October 5, 1999 |
| A method for enriching cancer cells such as prostate cancer cells in a bodily fluid sample is disclosed comprising (a) obtaining the sample comprising cancer cells and non-rare cells; (b) subjecting the sample to multiple density gradient separation comprising a first density gradient |
| 5912339 |
Oligonucleoside alkyl or arylphosphonate derivatives capable of crosslinking with or cleaving nu |
June 15, 1999 |
| A composition for inactivating a target nucleic acid which comprises an oligonucleoside alkyl or arylphosphonate analogue which is complementary to the sequence of the target nucleic acid and includes a functional group which reacts with the target nucleic acid to render the target nucle |
| 4757055 |
Method for selectively controlling unwanted expression or function of foreign nucleic acids in a |
July 12, 1988 |
| A process for selectively controlling or interfering with the effect or function of foreign nucleic acid in the presence of otherwise normal living cells which comprises determining the base sequence for said nucleic acid and binding the said nucleic acid with an appropriately prepar |
| 4591614 |
Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates |
May 27, 1986 |
| Oligonucleoside-3'-alkyl or aryl phosphonates are prepared by condensing (i) a 5'-protected nucleoside 3'-alkyl or aryl phosphonic imidazolide with (ii) a nucleoside or oligomer which is attached through its 3'-position to a polymer support. The process is advantageously carried out in t |
| 4587044 |
Linkage of proteins to nucleic acids |
May 6, 1986 |
| A nucleic acid-protein conjugate which is specific with respect to a selected living cell is prepared by linking said nucleic acid to a protein specific to said living cell. |
| 4511713 |
Process for selectively controlling unwanted expression or function of foreign nucleic acids in |
April 16, 1985 |
| A process for selectively controlling or interfering with the effect or function of foreign nucleic acid in the presence of otherwise normal living cells which comprises determining the base sequence for the nucleic acid and binding the nucleic acid with an appropriately prepared nonioni |
| 4507433 |
Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates |
March 26, 1985 |
| Process for synthesizing deoxyribonucleoside methylphosphonates on polystyrene polymer supports which involves condensing 5'-dimethoxytrityldeoxynucleoside 3'-methylphosphonates. The oligomers are removed from the support and the base protecting groups hydrolyzed by treatment with et |
| 4469863 |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
September 4, 1984 |
| Oligonucleoside alkyl-- or aryl phosphonates are nonionic analogues of nucleic acid which possess unique physical and biological properties. These properties enable the analogues to enter living cells intact and to bind with specifically selected nucleic acids within the cell. As a r |
| 4130641 |
Induction of interferon production by modified nucleic acid complexes |
December 19, 1978 |
| The present invention relates to the induction of interferon production in the cells of living organisms, including human beings. According to the invention, nucleic acid complexes, such as the polyriboinosinate and polycytidylate complex (rI.sub.n .multidot.rC.sub.n), are modified to |
| 4024222 |
Nucleic acid complexes |
May 17, 1977 |
| The present invention relates to the induction of interferon production in the cells of living organisms, including human beings. According to the invention, nucleic acid complexes, such as the polyriboinosinate and polycytidylate complex (rI.sub.n.rC.sub.n), are modified to yield unpair |
